HK1197159A1 - Pirfenidone and anti-fibrotic therapy in selected patients - Google Patents

Pirfenidone and anti-fibrotic therapy in selected patients Download PDF

Info

Publication number
HK1197159A1
HK1197159A1 HK14109929.1A HK14109929A HK1197159A1 HK 1197159 A1 HK1197159 A1 HK 1197159A1 HK 14109929 A HK14109929 A HK 14109929A HK 1197159 A1 HK1197159 A1 HK 1197159A1
Authority
HK
Hong Kong
Prior art keywords
pirfenidone
selected patients
fibrotic therapy
fibrotic
therapy
Prior art date
Application number
HK14109929.1A
Other languages
English (en)
Chinese (zh)
Inventor
Williamson Ziegler Bradford
Original Assignee
Intermune, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intermune, Inc. filed Critical Intermune, Inc.
Publication of HK1197159A1 publication Critical patent/HK1197159A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK14109929.1A 2011-05-25 2012-05-25 Pirfenidone and anti-fibrotic therapy in selected patients HK1197159A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201161489936P 2011-05-25 2011-05-25
US61/489,936 2011-05-25
US201161490057P 2011-05-26 2011-05-26
US61/490,057 2011-05-26
US201161523047P 2011-08-12 2011-08-12
US61/523,047 2011-08-12
US201161524961P 2011-08-18 2011-08-18
US61/524,961 2011-08-18
PCT/US2012/039538 WO2012162592A1 (en) 2011-05-25 2012-05-25 Pirfenidone and anti-fibrotic therapy in selected patients

Publications (1)

Publication Number Publication Date
HK1197159A1 true HK1197159A1 (en) 2015-01-09

Family

ID=47217770

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14109929.1A HK1197159A1 (en) 2011-05-25 2012-05-25 Pirfenidone and anti-fibrotic therapy in selected patients

Country Status (11)

Country Link
US (1) US20150164874A1 (https=)
EP (1) EP2713732A4 (https=)
JP (1) JP6170040B2 (https=)
KR (1) KR20140022048A (https=)
AU (1) AU2012258575B2 (https=)
CA (1) CA2835438A1 (https=)
HK (1) HK1197159A1 (https=)
IL (1) IL229226A0 (https=)
MX (1) MX2013013752A (https=)
SG (1) SG195110A1 (https=)
WO (1) WO2012162592A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5587184B2 (ja) 2007-06-20 2014-09-10 オースペックス・ファーマシューティカルズ・インコーポレイテッド 繊維症阻害剤としての置換ｎ−アリールピリジノン
JP2014507474A (ja) * 2011-03-08 2014-03-27 オースペックス・ファーマシューティカルズ・インコーポレイテッド 置換ｎ−アリールピリジノン
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
JP6799201B2 (ja) * 2013-07-31 2020-12-16 アヴァリン ファーマ インク． エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用
MX382781B (es) 2014-04-02 2025-03-13 Intermune Inc Piridinonas anti-fibroticas.
EP3194446B1 (en) 2014-09-18 2022-10-26 Cedars-Sinai Medical Center Compositions and methods for treating fibrosis
ES2764840T3 (es) * 2015-01-28 2020-06-04 Univ Bordeaux Uso de plerixafor para tratar y/o prevenir exacerbaciones agudas de la enfermedad pulmonar obstructiva crónica
WO2016140714A1 (en) * 2015-03-05 2016-09-09 The General Hospital Corporation Novel compositions and uses of metformin agents
KR20190122806A (ko) * 2017-03-13 2019-10-30 장피트 조합 치료요법용 약학 조성물
KR20200044066A (ko) * 2017-08-22 2020-04-28 바이오젠 엠에이 인코포레이티드 항-알파(v)베타(6) 항체를 함유하는 약제학적 조성물 및 투약 요법
WO2020236615A1 (en) * 2019-05-17 2020-11-26 The Regents Of The University Of California Mps modified peptides and use thereof
CN112239507A (zh) * 2019-07-17 2021-01-19 鸿运华宁（杭州）生物医药有限公司 ETA抗体与TGF-β Trap的融合蛋白质，以及其药物组合物和应用
EP3821946A1 (en) * 2019-11-12 2021-05-19 Université de Strasbourg Anti-claudin-1 monoclonal antibodies for the prevention and treatment of fibrotic diseases
KR20220109439A (ko) 2019-12-04 2022-08-04 이도르시아 파마슈티컬스 리미티드 섬유증 질환의 치료에서 사용하기 위한 아제티딘 lpa1 수용체 길항제와 피르페니돈 및/또는 닌테다닙의 조합
EP4117659A4 (en) * 2020-03-13 2024-04-03 Puretech Lyt 100, Inc. Methods of treating respiratory disease with deupirfenidone
CN114617890A (zh) * 2020-12-08 2022-06-14 四川夏派森医药科技有限公司 DH404在治疗SARS-CoV-2感染中的应用
CN112640887B (zh) * 2020-12-25 2022-05-13 武汉睿健医药科技有限公司 一种神经干细胞冻存液及其应用
WO2022266370A1 (en) * 2021-06-17 2022-12-22 Aria Pharmaceuticals, Inc. Sparsentan for treating idiopathic pulmonary fibrosis
CN114097807B (zh) * 2021-11-25 2023-05-05 兰州大学 巴多索隆类化合物在抗农业病原真菌中的用途
WO2023192646A1 (en) * 2022-03-31 2023-10-05 Puretech Lyt 100, Inc. Methods of treating fibrotic- and collagen-mediated diseases and disorders with deupirfenidone

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE420878T1 (de) * 2000-02-18 2009-01-15 Kyowa Hakko Kirin Co Ltd Isoxazol- und thiazolverbindungen und ihre verwendung als medikamente
AU2003244922A1 (en) * 2002-06-28 2004-01-19 The Administrators Of The Tulane Educational Fund 4-(4-methylpiperazin-1-ylmethyl)-n-(4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl)-benzamide for treating pulmonary fibrosis
US20070092488A1 (en) * 2003-05-16 2007-04-26 Intermune Inc. Methods of treating idiopathic pulmonary fibrosis
WO2005110478A2 (en) * 2004-04-13 2005-11-24 Intermune, Inc. Combination therapy for treating fibrotic disorders
WO2007119214A2 (en) * 2006-04-13 2007-10-25 Actelion Pharmaceuticals Ltd Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis
CA2914170C (en) * 2006-09-08 2018-10-30 Abbvie Bahamas Ltd. Interleukin-13 binding proteins
JP5587184B2 (ja) * 2007-06-20 2014-09-10 オースペックス・ファーマシューティカルズ・インコーポレイテッド 繊維症阻害剤としての置換ｎ−アリールピリジノン
AU2010206543A1 (en) * 2009-01-26 2011-07-07 Intermune, Inc. Methods for treating acute myocardial infarctions and associated disorders
GB2474748B (en) * 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists

Also Published As

Publication number Publication date
JP2014518880A (ja) 2014-08-07
NZ617415A (en) 2017-07-28
CA2835438A1 (en) 2012-11-29
KR20140022048A (ko) 2014-02-21
US20150164874A1 (en) 2015-06-18
EP2713732A1 (en) 2014-04-09
WO2012162592A1 (en) 2012-11-29
AU2012258575A1 (en) 2013-11-21
JP6170040B2 (ja) 2017-07-26
IL229226A0 (en) 2014-01-30
EP2713732A4 (en) 2014-12-03
SG195110A1 (en) 2013-12-30
AU2012258575B2 (en) 2017-03-02
MX2013013752A (es) 2014-08-01

Similar Documents

Publication Publication Date Title
HK1197159A1 (en) Pirfenidone and anti-fibrotic therapy in selected patients
IL231536A (en) Indazole-3-carboxamides, pharmaceuticals containing them and their use in the treatment of diseases
HK1210599A1 (en) Abuse deterrent pharmaceutical compositions for controlled release
ZA201309617B (en) Method of administration of 4-((1r,3s)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and the salts thereof in the treatment of schizophrenia
IL221874A (en) History of pyrimidine and their use in the treatment of respiratory diseases such as copd
PL2726470T3 (pl) Pochodne 1,2,4-tiadiazol-5-ilo piperazyny przydatne w leczeniu chorób neurodegeneracyjnych
WO2013117744A3 (en) Methods of treating fibrosis
GB2497453B (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV
ZA201402452B (en) Novel pyrimethanil formulations and uses thereof in the treatment of crops
SI2729469T1 (sl) Derivati orvinola in tevinola uporabni pri zdravljenju zlorabe mamil in alkohola
PT2590509T (pt) Método para a preparação e utilização de biocidas enriquecidos em radicais ativos antes da utilização
GB2515440B (en) Vesicular Formulations for use in the treatment of Rosacea
ZA201307058B (en) Use of polyaminoisoprenyl derrivatives in antobiotic or antisertic treatment
WO2014026013A3 (en) Methods for maintaining or improving health, well-being and/or a physiological function in a subject
ZA201503266B (en) Pyidone derivatives and uses thereof in the treatment of tuberculosis
EP3065548A4 (en) Fibrosis inhibiting compounds and methods of use thereof in the prevention or treatment of fibrosing diseases
IL230751A0 (en) New peptides, preparations containing them and used in methods to treat metabolic, cardiac and immune diseases
HK1209051A1 (en) A method of improving liver function
LT2699545T (lt) Nauji amino-pirolino dariniai ir jų naudojimas metabolinio sindromo prevencijai ir (arba) gydymui
WO2012146736A8 (en) Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease
WO2012119045A3 (en) Compositions and uses thereof to ameliorate pain
ZA201307847B (en) 4-(haldalkyl)(dimethyl) ammonio) butandates and use thereof in the treatment of cardiovascular disease
IL233354A0 (en) 2, 6-Dihalo-5-Alkoxy-4-converted-pyrimidines, pyrimidine-carbaldehydes, and methods of production and use
EP2934699A4 (en) PLOD2 GENE STIMULATORS AND USE OF SAID STIMULATORS FOR TREATING SKIN
TN2013000404A1 (en) Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease